ViroPharma, Eli Lilly deal

VPHM will acquire U.S. rights to manufacture and market LLY's Vancocin Pulvules, an oral capsule formulation of the antibiotic vancomycin. LLY will receive an upfront payment of $116 million for the drug, which is approved to treat enterocolitis caused by Staphylococcus aureus and antibiotic-associated pseudomembranous colitis caused by Clostridium difficile. LLY is eligible for royalties. ...